IL317047A - Solid forms of heterocyclylamides as irak4 inhibitors - Google Patents
Solid forms of heterocyclylamides as irak4 inhibitorsInfo
- Publication number
- IL317047A IL317047A IL317047A IL31704724A IL317047A IL 317047 A IL317047 A IL 317047A IL 317047 A IL317047 A IL 317047A IL 31704724 A IL31704724 A IL 31704724A IL 317047 A IL317047 A IL 317047A
- Authority
- IL
- Israel
- Prior art keywords
- heterocyclylamides
- solid forms
- irak4 inhibitors
- irak4
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263365387P | 2022-05-26 | 2022-05-26 | |
| PCT/EP2023/064007 WO2023227703A1 (en) | 2022-05-26 | 2023-05-25 | Solid forms of heterocyclylamides as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL317047A true IL317047A (en) | 2025-01-01 |
Family
ID=86692775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317047A IL317047A (en) | 2022-05-26 | 2023-05-25 | Solid forms of heterocyclylamides as irak4 inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250326757A1 (en) |
| EP (1) | EP4532499A1 (en) |
| JP (1) | JP2025518579A (en) |
| KR (1) | KR20250019656A (en) |
| CN (1) | CN119137125A (en) |
| AU (1) | AU2023274390A1 (en) |
| CA (1) | CA3253370A1 (en) |
| CL (1) | CL2024003580A1 (en) |
| IL (1) | IL317047A (en) |
| MX (1) | MX2024014493A (en) |
| WO (1) | WO2023227703A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20250114A1 (en) | 2021-06-03 | 2025-01-16 | Chinook Therapeutics Inc | SUBSTITUTED INDOL COMPOUNDS AND METHODS OF USING THEM |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3536685T3 (en) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | AZA COMPOUNDS SUBSTITUTED AS INHIBITORS OF IRAQ-4 |
| WO2017207386A1 (en) | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| CN110785418A (en) | 2017-06-21 | 2020-02-11 | 豪夫迈·罗氏有限公司 | Isoindolinone derivatives as IRAK4 modulators |
| US11866405B2 (en) * | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
-
2023
- 2023-05-25 US US18/870,598 patent/US20250326757A1/en active Pending
- 2023-05-25 CA CA3253370A patent/CA3253370A1/en active Pending
- 2023-05-25 JP JP2024569153A patent/JP2025518579A/en active Pending
- 2023-05-25 CN CN202380038088.3A patent/CN119137125A/en active Pending
- 2023-05-25 EP EP23728743.8A patent/EP4532499A1/en active Pending
- 2023-05-25 WO PCT/EP2023/064007 patent/WO2023227703A1/en not_active Ceased
- 2023-05-25 AU AU2023274390A patent/AU2023274390A1/en active Pending
- 2023-05-25 IL IL317047A patent/IL317047A/en unknown
- 2023-05-25 KR KR1020247041263A patent/KR20250019656A/en active Pending
-
2024
- 2024-11-22 CL CL2024003580A patent/CL2024003580A1/en unknown
- 2024-11-22 MX MX2024014493A patent/MX2024014493A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025518579A (en) | 2025-06-17 |
| EP4532499A1 (en) | 2025-04-09 |
| MX2024014493A (en) | 2025-01-09 |
| CL2024003580A1 (en) | 2025-03-14 |
| US20250326757A1 (en) | 2025-10-23 |
| KR20250019656A (en) | 2025-02-10 |
| CA3253370A1 (en) | 2023-11-30 |
| CN119137125A (en) | 2024-12-13 |
| WO2023227703A1 (en) | 2023-11-30 |
| AU2023274390A1 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE072981T2 (en) | Azaquinolines as inhibitors of cd38 | |
| IL317736A (en) | Compounds as inhibitors of axl | |
| EP4263520A4 (en) | Heterocyclic inhibitors of pcsk9 | |
| HUE068818T2 (en) | Inhibitors of transglutaminases | |
| IL304159A (en) | Composition of bl-8040 | |
| HUE068724T2 (en) | Inhibitors of transglutaminases | |
| PL4192812T3 (en) | Inhibitors of transglutaminases | |
| IL326152A (en) | Solid state forms of gusacitinib | |
| IL314800A (en) | Irak4 inhibitors | |
| ES3065110T3 (en) | Novel inhibitors of autotaxin | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL326433A (en) | Crystalline IRAK4 inhibitors | |
| IL326153A (en) | Solid state forms of gusacitinib | |
| IL319179A (en) | Solid state forms of denifanstat | |
| IL317760A (en) | Benzocarbazole derivatives as inhibitors of drp1 | |
| IL320661A (en) | Solid forms of complement factor b inhibitors | |
| CA3289184A1 (en) | Heteroarylindole inhibitors of apol-1 | |
| HK40120257A (en) | Irak4 inhibitors | |
| HK40086963A (en) | Inhibitors of sarm1 | |
| CA3280853A1 (en) | Inhibitors of synaptogyrin-3 expression | |
| HK40075448A (en) | Inhibitors of sarm1 | |
| GB202211318D0 (en) | Method of reducing nitro compounds | |
| GB202311665D0 (en) | Modification of composition | |
| HK40121003A (en) | Compounds as inhibitors of axl |